Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.52 |
| ▸ | TLR2 | O60603 | 2/20 | 0.51 |
| ▸ | MDM4 | O15151 | 3/20 | 0.47 |
| ▸ | TP53 | P04637 | 3/20 | 0.47 |
| ▸ | MDM2 | Q00987 | 7/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22702156 | 0.90 | TLR2 (0.57) | EPHX2TLR2MDM4TP53MDM2 | |
| SCHEMBL28686934 | 0.90 | TLR2 (0.57) | EPHX2TLR2MDM4TP53MDM2 | |
| SCHEMBL31369887 | 0.89 | TLR2 (0.53) | EPHX2TLR2MDM4TP53MDM2 | |
| SCHEMBL31369789 | 0.89 | FOLH1 (0.54) | EPHX2TLR2MDM4TP53MDM2 | |
| SCHEMBL31370150 | 0.83 | TLR2 (0.53) | EPHX2TLR2MDM4TP53MDM2 | |
| SCHEMBL31370101 | 0.83 | EPHX2 (0.52) | EPHX2TLR2MDM4TP53MDM2 | |
| SCHEMBL21837671 | 0.82 | MDM4 (0.50) | EPHX2TLR2MDM4TP53MDM2 | |
| SCHEMBL21837674 | 0.82 | MDM4 (0.50) | EPHX2TLR2MDM4TP53MDM2 | |
| SCHEMBL30889972 | 0.82 | MDM4 (0.50) | EPHX2TLR2MDM4TP53MDM2 | |
| SCHEMBL15133312 | 0.82 | TLR2 (0.48) | EPHX2TLR2MDM4TP53MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2024-12-05 | — | — | US | claimed |
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2024-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | BCAT1, BCAT2, PELP1 | EPHX2 4829/4885TLR2 4097/4885MDM4 2155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.